Massimo Offidani

25PUBLICATIONS
99CO-AUTHORS
Gene and molecular therapyHaematological tumoursMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 27, 2026
Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus.

|Aug 18, 2026
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy.

|Nov 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Sonia Morè, Massimo Offidani, Laura Corvatta

|Aug 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

|Apr 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

|Mar 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Fortunato Morabito, Enrica Antonia Martino, Monica Galli

Pageof 5

Frequent Collaborators

7 joint publications

Maria Teresa Petrucci

5 joint publications

Renato Zambello

5 joint publications

Elena Zamagni

5 joint publications

Francesca Gay